fashion -WSS

fashion

author：focus 2025-09-28 02:28:40 - browse：51447

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Glen Campbell's doctor discusses his public struggle with Alzheimer's

focus

WSS

Focused ultrasound for uterine fibroids: an uphill battle

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

It's time to retire 'poor historian' from clinicians' vocabularies

Prosthetic arm enables patients to feel the objects they grip

Addiction experts warn against a second 'war on drugs'

Arc Institute generative AI designs new CRISPR systems

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

With measles on the rise, a personal story of a devastating disease

Guidelines to prevent youth baseball injuries need more muscle

With measles on the rise, a personal story of a devastating disease

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Childbirth

The cancer drug shortage isn’t new — and neither are the solutions

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

knowledge

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Heat waves linked to early deliveries, preterm births in new study

Antibiotic resistance nearly killed me, so I'm raising awareness of it

With measles on the rise, a personal story of a devastating disease

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

hotspot

focus

hotspot

entertainment